代谢功能障碍相关脂肪性肝病无创药物治疗标准的验证与新策略
在1281例经活检的MASLD患者中验证现有无创治疗标准,发现仅39%和56%的F2/F3患者符合专家小组和AASLD标准,误诊率高且AUC低于0.60。提出两步策略(FIB-4≥1.30或糖尿病超重者FIB-4<1.30后肝硬度8-25 kPa)使阳性预测值达55%、阴性预测值77%、AUC 0.67,识别74%目标人群。
要点
- 现有无创标准漏诊约半数F2/F3治疗适应患者,误诊率23%-41%。
- 两步策略(FIB-4+代谢因素+肝硬度)提高识别效能,AUC 0.67。
- 该策略可识别74%目标人群,阳性预测值55%、阴性预测值77%。
核心结论
- 现有无创标准诊断效能欠佳,约半数有治疗指征患者将被漏治。
- 基于FIB-4、糖尿病和超重及肝硬度的两步策略可改善F2/F3识别。
研究设计与样本
- 横断面研究,纳入HEPAmet注册库1281例经活检的MASLD患者。
- 收集活检、合并症、生化及弹性成像数据,主要终点为活检诊断F2/F3。
主要发现
- 38%(486/1281)患者活检诊断为F2/F3 MASLD。
- 其中仅39%符合专家小组标准、56%符合AASLD实践指南的治疗条件。
- 现有标准误诊率:假阳性23%-41%,假阴性44%-60%,AUC均低于0.60。
- 两步策略阳性预测值55%、阴性预测值77%,AUC 0.67,识别74%目标人群。
关键数值与推荐
- 专家小组标准仅覆盖39%的F2/F3患者,AASLD指南覆盖56%。
- 两步策略第一步:FIB-4≥1.30,或糖尿病合并超重且FIB-4<1.30。
- 第二步:肝硬度8-25 kPa,阳性预测值55%、阴性预测值77%、AUC 0.67。
临床怎么用
- 临床启动resmetirom前应避免单独依赖现有无创标准。
- 可考虑两步策略筛选F2/F3患者,提高治疗适应证识别率。
局限性
- 横断面设计,外部验证队列信息未详述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Resmetirom is the first Food and Drug Administration-approved drug for metabolic dysfunction-associated liver disease (MASLD) in F2 and F3 patients with steatohepatitis. Noninvasive criteria have been proposed for initiating treatment; however, these have not been validated in clinical practice. We validated the proposed criteria and established new guidelines for initiating resmetirom treatment in clinical practice. METHODS: This was a cross-sectional study of 1281 MASLD patients from the HEPAmet registry with biopsy, comorbidity assessment, analytical profile, and elastography. Identification of MASLD with F2 and F3 was the main endpoint. A comprehensive review of international guidelines and expert consensus up to November 2024, focusing on therapeutic indications, was conducted. RESULTS: A total of 38% (n = 486 of 1281) of patients were diagnosed with MASLD F2 and F3 based on biopsy. However, only 39% and 56% of them met treatment eligibility criteria according to the Expert Panel Criteria and the American Association for the Study of Liver Diseases Practice Guidance, respectively. They included 45% of patients with early-stage fibrosis. False positive and false negative rates ranged from 23% to 41% and 44% to 60%, respectively, with area under the receiver-operating characteristic curve values below 0.60.These findings were validated in an external cohort. A two-step strategy, first selecting patients with Fibrosis-4 (FIB-4) ≥1.30, or with diabetes and overweight if FIB-4 <1.30, followed by a liver stiffness between 8 and 25 kPa, demonstrated higher positive (55%) and negative predictive values (77%) and higher area under the receiver-operating characteristic curve (0.67).This approach successfully identified 74% of the target population. CONCLUSIONS: The diagnostic performance and reliability of the proposed noninvasive criteria for initiating resmetirom treatment were suboptimal. About the half of patients with indication would not receive treatment under these criteria. A new strategy, using FIB-4, the presence of diabetes and overweight, and liver stiffness improved the identification of MASLD patients with F2 and F3.
引用
- Olveira A, Crespo J, Ibañez-Samaniego L, et al. Defining Noninvasive Criteria for Indicating Drug Therapy in Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice. Clin Gastroenterol Hepatol. 2025. PMID: 40907848. doi:10.1016/j.cgh.2025.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。